Targeting Strategies for Tissue-Specific Drug Delivery.
By Zongmin Zhao, Anvay Ukidve, Jayoung Kim, S. Mitragotri. Cell, 2020
853 citations recorded by the source corpus.
Off-target effects of systemically administered drugs have been a major hurdle in designing therapies with desired efficacy and acceptable toxicity. Developing targeting strategies to enable site-specific drug delivery holds promise in reducing off-target effects, decreasing unwanted toxicities, and thereby enhancing a drug's therapeutic efficacy. Over the past three decades, a large body of literature has focused on understanding the biological barriers that hinder tissue-specific drug delivery and strategies to overcome them. These efforts have led to several targeting strategies that modulate drug delivery in both the preclinical and clinical settings, including small molecule-, nucleic acid-, peptide-, antibody-, and cell-based strategies. Here, we discuss key advances and emerging concepts for tissue-specific drug delivery approaches and their clinical translation.
Subfields: Biomaterials, Biomedical Engineering, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/3d1554c112b89fff9e6c375cdc03656ac1eed7ab
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Feng Han
- Xiaojie Chen
- Yajun Wang
- T. Gong
- Zhong Chen
- Di Wu
- Yi Wang
- Qi Chen
Citations in the corpus
- The blood–brain barrier: Structure, regulation and drug delivery (2023, background): “15,16 On the basis of these strategies, functional materials with small size, tailored architecture and therapeutic motifs that facilitate the targeted drug delivery are widely engineered.”
- Nanomedicine in cancer therapy (2023, background): “28 29 – 31 Moving beyond the fi rst-generation cancer nanomedicines which aim to increase the accumulation of nanotherapeutics within solid tumors and thus to reduce off-target effects via tissue-speci fi c targeting, the second-generation cancer nanomedicines further strive for selective and…”